Introduction {#s1}
============

Depression in individuals with either major depressive disorder (MDD) or bipolar disorder (BD) is one of the leading causes of the global disease burden. Almost all current antidepressant drugs in clinical use require weeks to months to take full effect ([@CIT0001]), and a significant proportion of patients do not respond to available agents ([@CIT0029]). Ketamine, a noncompetitive *N*-methyl-D-aspartate receptor antagonist, has been safely used as an anesthetic and analgesic agent for many years. Recent clinical and preclinical research indicates that, in treatment-resistant MDD and BD subjects, a single subanesthetic dose of ketamine not only produces a rapid antidepressant effect within hours of administration, but also improves suicidal ideation ([@CIT0005]; [@CIT0050]; [@CIT0019]).

Activation of mammalian target of rapamycin (mTOR) and subsequent synaptogenesis in the prefrontal cortex (PFC) have been suggested to mediate ketamine's rapid antidepressant effects ([@CIT0036]; [@CIT0020]). The loss of synaptic function in the PFC, as well as the downregulation of synaptic proteins such as the postsynaptic density protein 95 (PSD95), were associated with depressive-like behaviors in a rodent model of chronic stress ([@CIT0037]). Through activation of the mTOR signaling pathway, acute injection of ketamine rapidly increased levels of these synaptic proteins and dendritic spine density; in contrast, inhibition of mTOR signaling prevented these synaptic actions and the antidepressant-like effects of ketamine in experimental animals ([@CIT0036]).

In clinical populations, repeated ketamine treatment is usually necessary to avoid subsequent relapse ([@CIT0050]; [@CIT0028]). However, ketamine has been used as a recreational drug and has a high risk of abuse. Repeated administration of ketamine can cause a variety of side effects, including hallucinations and cognitive impairments, and psychotomimetic symptoms ([@CIT0034]). In fact, ketamine was found to induce schizophrenia-like behaviors in humans ([@CIT0033]), and treating animals with subanesthetic doses of ketamine is a pharmacological model of schizophrenia ([@CIT0026]). In addition, administration of subanesthetic doses of ketamine increases oxidative stress in the rodent brain ([@CIT0052]; [@CIT0016]; [@CIT0014]). These adverse effects limit ketamine's potential for widespread clinical use.

Accumulating evidence indicates that the mood stabilizer lithium has strong antisuicidal properties ([@CIT0012]) and holds promise for treating other neurological and neurodegenerative diseases via its diverse mechanisms of action ([@CIT0010]; [@CIT0011]). Among them, lithium's ability to inhibit glycogen synthase kinase-3 (GSK-3), a ubiquitous serine-threonine kinase, has been considered critical to mediating its numerous mood-stabilizing and neuroprotective effects. Ketamine's rapid antidepressant effects require GSK-3 inhibition ([@CIT0006]). In addition, GSK-3 negatively regulated mTOR in mouse brain ([@CIT0045]). These findings indicate that lithium and ketamine may have a signaling convergence on the mTOR pathway and a possible mechanistic synergy on their antidepressant-like effects. The present study was undertaken to investigate whether combining ketamine with the mood stabilizer lithium could benefit ketamine's antidepressant effects in mice as well as protect against the oxidative stress associated with ketamine use.

Methods {#s2}
=======

Animals and Chronic Restraint Stress {#s3}
------------------------------------

Male CD-1 mice were purchased from Charles River Laboratory (Wilmington, MA), and chronic restraint stress was performed as previously described ([@CIT0043]). Briefly, mice were placed into a Plexiglas tube (2.5cm in diameter) individually for 2 hours once a day for 2 weeks ([supplementary Figure S1*a*](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu102/-/DC1)). All procedures for animal experiments were approved by the Animal Care and Use Committee of the National Institutes of Health (NIH).

Drug Treatment and Measurement of Serum Lithium Concentration {#s4}
-------------------------------------------------------------

Ketamine hydrochloride (10mg/mL; Vedco, St. Joseph, MO) was freshly diluted in saline (0.9%) before use and injected intraperitoneally at a volume of 10mL/kg of body weight. To ensure a steady-state serum concentration, mice were pretreated with lithium chloride through drinking water (600 or 1200mg/L) for 3 weeks prior to acute saline or ketamine challenge ([supplementary Figure S1*b*](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu102/-/DC1)). For postketamine lithium treatment, another cohort of stressed mice received lithium chloride treatment (1200mg/L) in drinking water following a single ketamine challenge ([supplementary Figure S1*c*](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu102/-/DC1)). Serum lithium concentrations of mice were measured by MEDTOX Laboratories (Saint Paul, MN; test code 60063).

Behavioral Tests {#s5}
----------------

Mice underwent the open-field test (OFT) 60 minutes after acute ketamine injection, followed by the forced swim test (FST) 30 minutes later. To investigate the behavioral effects of postketamine lithium treatment, both tests were repeated in the same order after 1 and 2 weeks of lithium treatment using the same group of mice ([supplementary Figure S1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu102/-/DC1)).

### OFT {#s6}

Under bright illumination from regular ceiling lights, mice were placed individually in the center of a clear open-field chamber (27.9 cm×27.9 cm×20cm), and their horizontal locomotor activities were measured by using an automated photo-beam open-field system (Med-Associates, St. Albans, VT) for 30 minutes.

### FST {#s7}

Briefly, each mouse was placed for 6 minutes in a 25-cm--high, 16-cm--diameter transparent cylindrical tank filled with room temperature water (\~22°C). Immobility was scored during the last 4 minutes of the session, and a decrease in swimming time was considered a measure of depressive-like behaviors. All test sessions were analyzed off-line by ANY-maze video-tracking system (Stoelting, Wood Dale, IL).

### Tail-Suspension Test {#s8}

Briefly, mice were suspended individually by the tail using nonirritating adhesive tape placed at about one-half the total tail length to a hook connected to a horizontal bar. Each test session lasted for 6 minutes and total immobility time was analyzed off-line by ANY-maze system (Stoelting).

Brain Sample Preparation and Western-Blot Analysis {#s9}
--------------------------------------------------

Brain tissues were homogenized in 20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid containing 0.32M sucrose and centrifuged at 700 *g* for 10 minutes at 4°C. The supernatants were centrifuged again at 14,000 *g* for 10 minutes at 4°C, and the pellets were resuspended in T-PER reagent (Thermo Scientific, Rockford, IL). Proteins were separated and transferred onto a nitrocellulose membrane. Blots were immunostained overnight at 4°C with primary antibody against total GSK-3β (BD, Franklin Lakes, NJ), phospho-GSK-3β at Ser9, total Akt (the serine/threonine kinase, also known as protein kinase B or PKB), phospho-Akt at Ser473, total extracellular signal-regulated kinases (ERKs), phospho-ERK at Thr202/Tyr204, total mTOR, phospho-mTOR at Ser2448, total P70S6 kinase (P70S6K), phospho-P70S6K at Thr389, total eukaryotic elongation factor-2 (eEF2), phospho-eEF2 at Thr56, PSD95 (all from Cell Signaling, Beverly, MA), total tropomyosin-related kinase B (TrkB; Millipore, Billerica, MA), phospho-TrkB at Tyr817, or the house-keeping gene β-actin (Abcam, Cambridge, MA). Membranes were then incubated with secondary antibodies (LI-COR, Lincoln, NE) for 1 hour at room temperature. Finally, blotted proteins were detected and quantified using the Odyssey infrared imaging system (LI-COR).

Analysis of Oxidative Stress {#s10}
----------------------------

Mice were sacrificed by decapitation 20 minutes after acute ketamine challenge, and the brains were dissected and homogenized according to the buffer requirements of each assay.

### Thriobarbituric Acid Reactive Substances Assay {#s11}

Assay of thriobarbituric acid reactive substances, byproducts of lipid peroxidation, was performed according to the manufacturer's instructions (Cayman Chemical, Ann Arbor, MI). The production of malondialdehyde was normalized by protein concentration.

### Catalase Activity Assay {#s12}

This assay was performed according to the manufacturer's instructions (Cayman Chemical). The production rate of formaldehyde was normalized by protein concentration.

### Glutathione Assay {#s13}

Analyses of reduced and oxidized glutathione levels were conducted per the manufacturer's instructions (Cayman Chemical). The oxidized glutathione content was expressed as the ratio to total (reduced and oxidized) glutathione.

Analysis of Dendritic Spine Density {#s14}
-----------------------------------

Mice were sacrificed and brains were subjected to Golgi-staining (FD NeuroTechnologies, Columbia, MD) at the time indicated. Briefly, coronal sections of 100 µm in thickness were prepared, and both basal and apical dendrites (\~50 and \~100 µm from soma, respectively) of pyramidal neurons in layer V of medial PFC (anterior cingulate and prelimbic) were chosen for quantitative analysis. Images were captured by an Olympus BX61 microscope, and the length of dendritic segments was determined by using ImageJ software from NIH. Spine numbers in \~30-µm segments were measured manually by investigators blind to the experimental conditions. Two segments from each neuron were analyzed, and the results were expressed as number of spines per µm.

Statistical Analyses {#s15}
--------------------

All statistical analyses were performed using GraphPad Prism (GraphPad, San Diego, CA). Data are expressed as mean±SEM and analyzed using *t* test or 1-way analysis of variance. When necessary, multiple comparisons between groups were assessed with posthoc Student--Newman--Keuls multiple comparison test. Statistical significance was considered at *P*\<.05.

Results {#s16}
=======

Antidepressant-Like Effects of Ketamine in CD-1 Mouse Model of Stress {#s17}
---------------------------------------------------------------------

To mimic a clinical situation, the chronic restraint stress paradigm was used for the detection of antidepressant-like effects of ketamine and lithium. The depressive-like behaviors of this stress model can be suppressed by 20mg/kg of the antidepressant desipramine ([@CIT0043]). In the present study, chronic restraint paradigm markedly increased immobility time in the FST and tail suspension test (TST) by 140.8± 12.1% (*t*(14)=2.93, *P*=.011) and 124.2±7.6% (*t*(14)=2.59, *P=*.021), respectively, compared with unstressed mice ([Figure 1a](#F1){ref-type="fig"}). A wide range of ketamine doses (1--100mg/kg) has been reported to effectively produce antidepressant-like effects in various mouse strains ([@CIT0040]; [@CIT0027]; [@CIT0032]; [@CIT0044]; [@CIT0007]). We thus performed a dose response test in our CD-1 mouse model of stress and found that the minimum dose for ketamine to suppress immobility time in the FST was 50mg/kg (72.2±6.5% of control, *F*\[3, 26\] =3.02, *P*\<.05) ([Figure 1b](#F1){ref-type="fig"}). This effective dose of ketamine was confirmed by a decreased immobility time in the TST performed 24 hours after FST (72.6±8.7% of control, *F*\[3, 26\] =0.046, *P*\<.05) ([Figure 1b](#F1){ref-type="fig"}). However, mice that received this dose of ketamine also exhibited hyperlocomotion as measured by the OFT (169.8±13.2% of control, *F*\[3, 26\] =5.03, *P* \<.01) ([Figure 1c](#F1){ref-type="fig"}).

![Dose response of acute ketamine challenge in stressed mice. Chronic restraint stress produced depressive-like behaviors in CD-1 mice, as assessed by increased immobility time in the forced swim test (FST) and tail-suspension test (TST) (*a*). In stressed mice, acute injection of ketamine at a dose of 50mg/kg not only significantly suppressed immobility in both tests (*b*), but also increased locomotor activity measured by the open-field test (OFT) (*c*). Data are mean±SEM (n =6--8). +*P*\<.05, *t* test; \**P*\<.05, \*\**P*\<.01, compared with control groups, according to Student--Newman--Keuls multiple comparison test after a 1-way analysis of variance (ANOVA).](ijnppy_pyu102_f0001){#F1}

Preketamine Treatment with a Subtherapeutic Dose of Lithium Potentiates the Antidepressant-Like Effects Induced by a Low Dose of Ketamine {#s18}
-----------------------------------------------------------------------------------------------------------------------------------------

Long-term treatment is usually necessary for lithium to reach a steady-state serum level and exert its effects. Our pilot study indicated that the serum concentration of lithium in CD-1 mice after 3 weeks of treatment with 600mg/L of the drug in drinking water (0.202±0.029 mEq/L; n=8) was below the therapeutic levels for human patients with BD (\~0.5--1.2 mEq/L) (American Psychiatric Association, 2002). No differences were observed for measures of body weight ([Figure 2a](#F2){ref-type="fig"}) or locomotor activity ([Figure 2b](#F2){ref-type="fig"}) between controls and mice that received this dose of lithium for 3 weeks.

![Preketamine treatment with a subtherapeutic dose of lithium potentiates a low dose of ketamine-induced antidepressant-like effects. In CD-1 mice, long-term treatment with a sub- (600mg/L) or low therapeutic dose (1200mg/L) of lithium chloride in drinking water for 3 weeks did not affect body weight (*a*) or locomotor activity (*b*). Pretreatment with 600mg/L of lithium alone had no effect on immobility time in saline-challenged stressed mice (lithium alone group), but significantly potentiated the response induced by a very low dose of ketamine (2.5mg/kg) in the forced swim test (FST) (lithium + ketamine group) (*c*). The locomotor activity of stressed mice measured by the open-field test (OFT) was not affected by any given treatment (*d*). Data are mean±SEM (n =6--12). \**P*\<.05, \*\**P*\<.01, according to Student--Newman--Keuls multiple comparison test after a 1-way analysis of variance (ANOVA).](ijnppy_pyu102_f0002){#F2}

In stressed mice, pretreatment with 600mg/L of lithium alone had no significant effects on immobility time in the FST ([Figure 2c](#F2){ref-type="fig"}). Interestingly, stressed mice that had been pretreated with this subtherapeutic dose of lithium had a robust antidepressant-like response to acute challenge with a very low dose (2.5mg/kg) of ketamine (78.76±4.38% of control, *F*\[5, 52\] =4.34, *P\<*.05) ([Figure 2c](#F2){ref-type="fig"}) that, administered alone, had no significant antidepressant effect ([Figure 1b](#F1){ref-type="fig"}). Treatment with this dose of lithium alone or together with a 2.5-mg/kg ketamine challenge did not affect locomotor activity of stressed mice ([Figure 2d](#F2){ref-type="fig"}). These data show that the combination of "ineffective" doses of lithium and ketamine can produce synergy on antidepressant-like effects and suggest a signaling convergence between these two drugs.

Preketamine Treatment with a Subtherapeutic Dose of Lithium Potentiates the Activation of mTOR/BDNF-TrkB Signaling Pathways Induced by a Low Dose of Ketamine {#s19}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

As mentioned above, activation of the mTOR pathway in the PFC is critical to ketamine's rapid antidepressant-like effect. In the present study, mice that had undergone chronic restraint stress showed a trend towards decreased phosphorylation of mTOR and its downstream effector P70S6K in the PFC, though the effect was not statistically significant compared with unstressed mice ([Figure 3a](#F3){ref-type="fig"}). In stressed mice, acute injection with a behaviorally ineffective dose (2.5mg/kg) of ketamine or pretreatment with 600mg/L of lithium alone had no significant effects, while a combination with these two treatments strongly enhanced the phosphorylation of mTOR (136.30±6.47%, *P*\<.01) and P70S6K (163.25±11.58%, *P*\<.01) in the PFC ([Figure 3*a*](#F3){ref-type="fig"}).

![Preketamine treatment with a subtherapeutic dose of lithium potentiates the activation of mammalian target of rapamycin (mTOR)/brain-derived neurotrophic factor (BDNF)-tropomyosin-related kinase B (TrkB) signaling pathways induced by acute challenge with a low dose of ketamine. Mice were pretreated with 600mg/L of lithium for 3 weeks, and brain tissues were collected 60 minutes after a single injection of saline (lithium alone group) or a very low dose (2.5mg/kg) of ketamine (lithium + ketamine group). Typical Western blots and quantified results are shown. The phosphorylation levels of mTOR, P70S6K, eukaryotic elongation factor-2 (eEF2), and the expression of postsynaptic density protein 95 (PSD95) (*a*), as well as the phosphorylation levels of TrkB, Akt, extracellular signal-regulated kinase (ERK), and glycogen synthase kinase-3β (GSK-3β) (*b*) in the prefrontal cortex (PFC) were normalized to the levels of total protein or β-actin and expressed as percentage of control group. Data are mean±SEM (n =4--8). ++*P*\<.01, *t* test; \**P*\<.05, \*\**P*\<.01, according to Student--Newman--Keuls multiple comparison test after a 1-way analysis of variance (ANOVA). P, phosphorylated protein; T, total protein; US, unstressed.](ijnppy_pyu102_f0003){#F3}

We also found that stressed mice showed increased phosphorylation of eEF2 (145.37±9.96% of unstressed mice, *t*(12) =4.47, *P*\<.01) ([Figure 3*a*](#F3){ref-type="fig"}), an essential component required for polypeptide elongation in protein synthesis ([@CIT0048]). The activity of eEF2 is negatively regulated by its phosphorylation at threonine 56 induced by eEF2 kinase, a downstream effector of the mTOR pathway that is inhibited by P70S6K ([@CIT0048]). Again, pretreatment with 600mg/L of lithium together with acute injection of 2.5mg/kg of ketamine robustly decreased eEF2 phosphorylation (60.25±4.46%, *P*\<.05) and upregulated the expression of synaptic protein PSD95 (150.44±14.91%, *P*\<.05) in the PFC compared with control stressed mice. Neither drug alone had significant effects ([Figure 3*a*](#F3){ref-type="fig"}).

In addition to the mTOR pathway, GSK-3β inhibition ([@CIT0006]) and acute increases in brain-derived neurotrophic factor (BDNF) protein levels ([@CIT0024]; [@CIT0003]), including activation of the downstream effectors Akt and ERK ([@CIT0036]), are also necessary for ketamine's rapid antidepressant actions. Similar to the observations described above, we found that only pretreatment with 600mg/L of lithium plus subsequent challenge with 2.5mg/kg of ketamine significantly increased phosphorylation levels of TrkB (a BDNF receptor; 123.02±6.49%, *P*\<.05), Akt (184.18±8.57%, *P*\<.01), ERK (156.59±14.37%, *P*\<.05), and GSK-3β (206.21±10.40%, *P*\<.01) ([Figure 3*b*](#F3){ref-type="fig"}) in the PFC compared with control stressed mice. Treatment with either drug alone had no significant effects. It is interesting to note that chronic restraint stress alone markedly decreased GSK-3β phosphorylation in this brain region (76.10±5.23%, *t*(12) =3.69, *P*\<.01) compared with unstressed mice ([Figure 3*b*](#F3){ref-type="fig"}).

Preketamine Treatment with a Low Therapeutic Dose of Lithium Suppresses Acute Ketamine-induced Oxidative Stress {#s20}
---------------------------------------------------------------------------------------------------------------

In our mouse model of stress, we found that acute injection with ketamine at a dose that produces an antidepressant-like effect (50mg/kg) markedly increased lipid peroxidation (141.49±7.29% of control, *P*\<.01) ([Figure 4*a*](#F4){ref-type="fig"}), catalase activity (120.64±5.79% of control, *P*\<.01) ([Figure 4*b*](#F4){ref-type="fig"}), and levels of oxidized glutathione (130.90±7.75% of control, *P*\<.01) ([Figure 4*c*](#F4){ref-type="fig"}) in the PFC 20 minutes after injection. Similar results were also observed in the hippocampus (lipid peroxidation: 173.40±14.26%, *P*\<.01; catalase activity: 145.69±9.92%, *P*\<.01; oxidized glutathione: 142.60±6.62%, *P*\<.05) and striatum (lipid peroxidation: 140.86±12.37%, *P*\<.01; catalase activity: 121.37±6.14%, *P*\<.05; oxidized glutathione: 138.70±7.27%, *P*\<.05; compared with control stressed mice) ([Figure 4](#F4){ref-type="fig"}).

![Preketamine treatment with a low therapeutic dose of lithium suppresses acute ketamine-induced oxidative stress. Acute ketamine injection at a dose that produces antidepressant-like effect (50mg/kg) markedly increased lipid peroxidation (*a*), catalase activity (*b*), and the levels of oxidized glutathione (*c*) in the prefrontal cortex (PFC), hippocampus (HPC), and striatum (STR) of stressed mice 20 minutes after injection. Compared with control stressed mice, preketamine treatment with 1200mg/L of lithium for 3 weeks robustly suppressed the oxidative metabolism markers induced by acute ketamine (lithium + ketamine group) in these brain regions. Data are mean±SEM (n =6--10). \**P*\<.05, \*\**P*\<.01, according to Student--Newman--Keuls multiple comparison test after a one-way analysis of variance (ANOVA).](ijnppy_pyu102_f0004){#F4}

To investigate whether lithium can protect against the oxidative stress induced by ketamine, mice were pretreated with a higher dose (1200mg/L) of lithium in drinking water for 3 weeks before ketamine challenge. The serum concentration of lithium after 3 weeks of treatment with this dose was at the lower end (0.483±0.052 mEq/L; n=8) of the therapeutic spectrum for human patients with BD. Long-term treatment with this dose of lithium did not affect either body weight ([Figure 2*a*](#F2){ref-type="fig"}) or locomotor activity of mice ([Figure 2](#F2){ref-type="fig"}). Compared with control stressed mice, lithium pretreatment robustly suppressed ketamine-induced lipid peroxidation (89.35±13.09%, *P*\<.01) ([Figure 4*a*](#F4){ref-type="fig"}), catalase activity (85.16±3.40%, *P*\<.01) ([Figure 4*b*](#F4){ref-type="fig"}), and levels of oxidized glutathione (103.49±7.73%, *P*\<.01) ([Figure 4*c*](#F4){ref-type="fig"}) in the PFC. These ketamine-induced oxidative metabolism markers in the hippocampus (lipid peroxidation: 121.23±10.34%, *P*\<.01; catalase activity: 109.80±7.42%, *P*\<.01; oxidized glutathione: 106.85±10.40%, *P*\<.05) and striatum (lipid peroxidation: 94.04±7.48%, *P*\<.01; catalase activity: 100.37±5.64%, *P*\<.01; oxidized glutathione: 106.12±8.19%, *P*\<.05, compared with control stressed mice) were also reduced by lithium pretreatment ([Figure 4](#F4){ref-type="fig"}). Although stress is an important contributor to intracellular reactive oxygen species (ROS) generation, we did not observe a significant increase in ROS formation induced by chronic restraint stress (data not shown).

Postketamine Treatment with a Low Therapeutic Dose of Lithium Maintains the Antidepressant-Like Effect and Prevents the Hyperlocomotion Induced by a Single Injection of Ketamine {#s21}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Although a single infusion of ketamine exerts rapid antidepressant effects, these typically last for only 1 week in human patients and experimental animals ([@CIT0005]; [@CIT0050]; [@CIT0003]; [@CIT0028]). We thus sought to investigate whether lithium treatment after ketamine injection might prolong its antidepressant-like effect in our mouse stress model, thereby assessing its potential as a relapse prevention therapeutic strategy.

To ensure the potential effects of lithium, the higher dose (1200mg/L) was preferred in this part of tests. Treatment with this dose of lithium that produced a low therapeutic serum concentration for 1 ([Figure 5*a*](#F5){ref-type="fig"}) or 2 weeks ([Figure 5*b*](#F5){ref-type="fig"}) produced no antidepressant-like effect in the FST in saline-challenged stressed mice. In contrast, the stressed mice that had received a single injection with 50mg/kg of ketamine still showed decreased immobility time in the FST after 1 week compared with control (*F*\[3, 28\] =3.69, *P* =0.024). Postketamine treatment with 1200mg/L of lithium for 1 week did not further suppress this effect ([Figure 5*a*](#F5){ref-type="fig"}). Consistent with findings in the literature, the ketamine-induced antidepressant-like effects were not sustained for 2 weeks ([Figure 5*b*](#F5){ref-type="fig"}). However, the immobility time of mice that received both ketamine injection and lithium treatment remained decreased after 2 weeks compared with control (*F*\[3, 28\] =5.18, *P* =.005) ([Figure 5*b*](#F5){ref-type="fig"}). On the other hand, the hyperlocomotion associated with ketamine injection lasted for at least 2 weeks ([Figure 5*c*](#F5){ref-type="fig"}-*d*). Interestingly, this ketamine-induced long-lasting hyperlocomotion was completely prevented by postketamine lithium treatment measured at either 1 (*F*\[3, 28\] =3.88, *P* =.019) ([Figure 5*c*](#F5){ref-type="fig"}) or 2 weeks (*F*\[3, 28\] =3.73, *P* =.023) ([Figure 5*d*](#F5){ref-type="fig"}) following ketamine injection, while the same lithium treatment did not affect the OFT in saline-challenged mice.

![Postketamine treatment with a low therapeutic dose of lithium prolongs the antidepressant-like effects and prevents the hyperlocomotion induced by a single injection of ketamine. Stressed mice received long-term treatment with 1200mg/L of lithium in drinking water immediately after a single injection of saline (lithium alone group) or 50mg/kg of ketamine (ketamine + lithium group). The effects of lithium on ketamine-induced antidepressant-like effects (assessed by the forced swim test \[FST\]) (*a*-*b*) and locomotor activity (assessed by the open-field test \[OFT\]) (*c*-*d*) were measured after 1 (*a*, *c*) and 2 weeks (*b*, *d*) of lithium treatment. Data are mean±SEM (n =8).\**P*\<.05, \*\**P*\<.01, according to Student--Newman--Keuls multiple comparison test after a 1-way analysis of variance (ANOVA).](ijnppy_pyu102_f0005){#F5}

Postketamine Treatment with a Low Therapeutic Dose of Lithium Prolongs the Activation of mTOR/BDNF-TrkB Signaling Pathways Induced by a Single Injection of Ketamine {#s22}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

One week after a single injection of 50mg/kg ketamine, we observed a trend towards elevated phosphorylation of mTOR (123.17±15.73%, not significant), P70S6K (154.76±15.36%, *P*\<.05) ([Figure 6*a*](#F6){ref-type="fig"}), TrkB (122.19±5.18%, not significant), Akt (137.52±8.42%, *P*\<.05), ERK (120.39±14.93%, not significant), and GSK-3β (156.77±13.79%, *P*\<.05) ([Figure 7*a*](#F7){ref-type="fig"}), while eEF2 phosphorylation was decreased (76.56±4.47%, *P*\<.05) ([Figure 6*a*](#F6){ref-type="fig"}). Although not significant, PSD95 expression also appeared to be upregulated in the PFC (124.79±11.27%) compared with control stressed mice ([Figure 6*a*](#F6){ref-type="fig"}). Treatment with 1200mg/L of lithium for 1 week had no significant effects in saline-challenged stressed mice and did not affect the regulatory effects of ketamine described above ([Figures 6*a*](#F6){ref-type="fig"} and [7*a*](#F7){ref-type="fig"}).

![Postketamine treatment with a low therapeutic dose of lithium maintains the activation of the mammalian target of rapamycin (mTOR) signaling pathway induced by a single injection of ketamine. Stressed mice received long-term treatment with 1200mg/L of lithium in drinking water immediately after a single injection of saline (lithium alone group) or 50mg/kg of ketamine (ketamine + lithium group), and brain tissues were collected after 1 (*a*) or 2 weeks (*b*) of lithium treatment. Typical Western blots and quantified results are shown. Phosphorylation levels of mTOR, P70S6K, eukaryotic elongation factor-2 (eEF2), and the expression of postsynaptic density protein 95 (PSD95) in the prefrontal cortex (PFC) were normalized to the levels of total protein or β-actin and expressed as percentage of control group. Data are mean±SEM (n =6--8). \**P*\<.05, \*\**P*\<.01, according to Student--Newman--Keuls multiple comparison test after a 1-way analysis of variance (ANOVA). P, phosphorylated protein; T, total protein; US, unstressed.](ijnppy_pyu102_f0006){#F6}

![Postketamine treatment with a low therapeutic dose of lithium maintains the inhibition of glycogen synthase kinase-3β (GSK-3β) and activation of brain-derived neurotrophic factor (BDNF)-tropomyosin-related kinase B (TrkB) signaling pathway induced by a single injection of ketamine. Stressed mice received long-term treatment with 1200mg/L of lithium in drinking water immediately after a single injection of saline (lithium alone group) or 50mg/kg of ketamine (ketamine + lithium group), and brain tissues were collected after 1 (a) or 2 weeks (b) of lithium treatment. Typical Western blots and quantified results are shown. Phosphorylation levels of TrkB, Akt, extracellular signal-regulated kinase (ERK), and GSK-3β in the prefrontal cortex (PFC) were normalized to the levels of total protein and expressed as percentage of control group. Data are mean±SEM (n =6--8). ++*P*\<.01, *t* test; \**P*\<.05, \*\**P*\<.01, according to Student--Newman--Keuls multiple comparison test after a 1-way analysis of variance (ANOVA). P, phosphorylated protein; T, total protein; US, unstressed.](ijnppy_pyu102_f0007){#F7}

Compared with unstressed mice, GSK-3β phosphorylation remained significantly decreased in the PFC of stressed mice 1 week (68.23±6.46%, *t*(10) =3.33, *P*\<.01) ([Figure 7*a*](#F7){ref-type="fig"}), but not 2 weeks, after chronic restraint stress ([Figure 7*b*](#F7){ref-type="fig"}). Similar to the observation in the behavioral study, the cellular changes induced by ketamine alone lasted for only approximately 1 week. No significant effects were obtained 2 weeks after a single injection with 50mg/kg of ketamine ([Figures 6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). However, postketamine treatment with lithium for 2 weeks prolonged and potentiated the regulatory effects of ketamine on the expression of PSD95 (141.91±11.25%, *P*\<.01) as well as phosphorylation of mTOR (145.15±12.02%, *P*\<.05), P70S6K (153.70±8.97%, *P*\<.05), eEF2 (71.30±5.25%, *P*\<.05) ([Figure 6b](#F6){ref-type="fig"}), TrkB (150.38±19.44%, *P*\<.05), Akt (142.66±7.60%, *P*\<.05), ERK (146.24±7.86%, *P*\<.05), and GSK-3β (139.08±5.20%, *P*\<.05) ([Figure 7*b*](#F7){ref-type="fig"}) compared with control stressed mice. These results suggest that the behavioral effects of lithium treatment on ketamine's antidepressant-like effects appear to be closely associated with GSK-3β inhibition and stimulation of the mTOR/BDNF-TrkB signaling pathways.

Postketamine Treatment with a Low Therapeutic Dose of Lithium Maintains the Restoration of Dendritic Spine Density Induced by a Single Injection of Ketamine {#s23}
------------------------------------------------------------------------------------------------------------------------------------------------------------

An increase in the density of dendritic spines in the medial PFC has been reported to be one of the mTOR-dependent mechanisms underlying ketamine's antidepressant-like effects ([@CIT0036]; [@CIT0038]). We thus analyzed the effects of postketamine lithium treatment on alterations in spine density induced by a single injection of ketamine. Compared with unstressed mice, the spine densities were found decreased in the medial PFC at 1 (69.55±3.20%, *t*(70) =7.78, *P*\<.01) and 2 weeks (78.85±3.96%, *t*(70) =3.81, *P*\<.01) after chronic restraint stress ([Figure 8](#F8){ref-type="fig"}). Compared with control stressed mice, the spine densities in this brain region still remained increased 1 week after a single injection with 50mg/kg of ketamine (134.79±6.62% of control, *F*\[3, 140\] =15.80, *P* \<.01), while this effect was not further potentiated by 1-week postketamine treatment with 1200mg/L of lithium (153.07±5.50% of control) ([Figure 8*a*](#F8){ref-type="fig"}-[*b*](#F8){ref-type="fig"}). Ketamine-induced normalization in spine density was not sustained for 2 weeks (103.71±5.01% of control, not significant). However, the density of spines remained elevated in the medial PFC of mice that received both ketamine injection and lithium treatment for 2 weeks compared with control stressed mice (128.31±4.36%, *F*\[3, 140\] =6.26, *P* \<.01) ([Figure 8*a*](#F8){ref-type="fig"}, [*c*](#F8){ref-type="fig"}).

![Postketamine treatment with a low therapeutic dose of lithium maintains the dendritic spine density restored by a single injection of ketamine. Representative Golgi-stained sections of spines on dendrites of pyramidal neurons in layer V of medial prefrontal cortex (PFC) are shown (scale bar indicates 5 µm) (*a*). Stressed mice received long-term treatment with 1200mg/L of lithium in drinking water immediately after a single injection of saline (lithium alone group) or 50mg/kg of ketamine (ketamine + lithium group). Quantified data were obtained from brain samples of unstressed (US) and stressed mice after 1 (*b*) or 2 weeks (*c*) of lithium treatment. Data are mean±SEM (n =36). ++*P*\<.01, *t* test; \*\**P*\<.01, according to Student--Newman--Keuls multiple comparison test after a 1-way analysis of variance (ANOVA).](ijnppy_pyu102_f0008){#F8}
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The present study found that pretreatment of stressed mice with 600mg/L of lithium markedly potentiated the antidepressant-like effect induced by 2.5mg/kg of ketamine, which by itself was ineffective. This is particularly important, because this low-dose combination might avoid the possible adverse effects associated with individual drugs. Indeed, we observed an elevated level of oxidative stress in the mouse brain in conjunction with ketamine's rapid antidepressant-like action, but this side effect was mitigated by pretreatment with 1200mg/L of lithium. Also notable was that the antidepressant-like effect induced by a single injection with 50mg/kg of ketamine was prolonged by postketamine treatment with 1200mg/L of lithium for at least 2 weeks. We demonstrated that the behavioral benefits of lithium treatment on ketamine's antidepressant effects were associated with GSK-3β inhibition, stimulation of the mTOR/BDNF-TrkB signaling pathways, and restoration in dendritic spine density in the medial PFC. These data support a recent rat study showing that GSK-3 inhibition potentiates the antidepressant-like effects of subthreshold doses of ketamine ([@CIT0038]), and are consistent with a clinical observation that lithium-treated BD patients expressed greater antianhedonic responses to ketamine ([@CIT0005a]).

Presumably due to significant strain differences in sensitivity to ketamine, the effective dose (50mg/kg) for ketamine to produce antidepressant-like effects in our mouse model of stress was high and caused hyperlocomotion. However, this dose was the result of our dose-response experiment and is also comparable with other studies. For example, acute ketamine was reported to induce antidepressant-like effects at doses of 30 to 100mg/kg in male ICR mice using FST ([@CIT0027]), 50 and 66mg/kg in male C57BL/6J/Han mice using TST ([@CIT0032]), and 50mg/kg in male Swiss mice using FST ([@CIT0044]). Mice that received 50mg/kg of ketamine challenge indeed appeared slightly impaired during the first 30 minutes after injection; however, no obvious lingering sedative or anesthetic conditions were observed while performing the OFT and FST. In addition, since hyperlocomotion is known to affect immobility in the FST, we performed TST as an additional indicator in the ketamine dose-response study. Although also dependent on a motor readout, the TST avoids the need of swimming and has been suggested to be more relevant for the study of animals with compromised motor coordination ([@CIT0013]). Most importantly, stressed mice that received both ketamine and lithium treatment showed decreased immobility time in the FST but did not exhibit hyperlocomotion ([Figures 2](#F2){ref-type="fig"} and [5](#F5){ref-type="fig"}).

Compared with other published reports ([@CIT0017], [@CIT0018]; [@CIT0025]), the serum lithium concentrations of stressed mice in our study were relatively low. We speculated that this discrepancy might be caused by restraint stress, which may reduce water consumption, or because of the difference in the experimental conditions (eg, sucrose in water) or animals. As expected, long-term treatment with either 600 or 1200mg/L of lithium alone produced no effects on behavioral tests and most of the biochemical measurements (including GSK-3β phosphorylation). This may explain why the potentiation effects of postketamine lithium were obscure when ketamine's effects were still evident (1 week) but became obvious after ketamine's effect subsided (2 weeks). In fact, our preliminary data showed that treatment with 2400mg/L of lithium not only produced a therapeutic serum concentration (0.897±0.250 mEq/L, n =8) in stressed mice but also decreased immobility time in the FST (data not shown).

Ketamine-induced increase in dendritic spine density in the medial PFC was identified dependent on activation of mTOR pathway ([@CIT0036]) and can be mimicked by GSK-3 inhibition ([@CIT0038]). Studies have noted that the expression of both mTOR and P70S6K is decreased in the postmortem brain of depressed subjects ([@CIT0030]), suggesting a compromised mTOR pathway. We observed a trend towards decreased phosphorylation of these 2 proteins ([Figure 3*a*](#F3){ref-type="fig"}) and a sustained reduction in dendritic spine density in the PFC of stressed mice ([Figure 8](#F8){ref-type="fig"}). In addition, rats that suffered from chronic mild stress showed increased GSK-3β expression in the hippocampus ([@CIT0046]), and elevated GSK-3 activity was found in postmortem samples from individuals with MDD ([@CIT0031]). Consistent with previous hippocampal data ([@CIT0043]), chronic restraint stress also significantly decreased GSK-3β phosphorylation in the PFC ([Figure 3*b*](#F3){ref-type="fig"}), and this effect lasted for at least 1 week after chronic restraint stress ended ([Figure 7](#F7){ref-type="fig"}). These findings provide additional justification for the use of this restraint paradigm in the present study. It is interesting to note that the increased GSK-3β phosphorylation in rat PFC observed during ketamine's rapid antidepressant actions was not affected by mTOR or P70S6K antagonists ([@CIT0051]), further supporting the notion that GSK-3β is an upstream regulator of mTOR.

BDNF plays a central role in synaptic plasticity and mediates the clinical efficacy of antidepressants and anxiolytic drugs. Ketamine-induced antidepressant-like effects were absent in BDNF knockout mice ([@CIT0003]) and abolished by inhibitors of Akt or ERK; both are upstream regulators of mTOR ([@CIT0036]). We found that lithium treatment also potentiated and prolonged acute ketamine's effect on phosphorylation of TrkB, Akt, and ERK in stressed mice, suggesting the activation of this pathway. By inhibiting GSK-3β, lithium was demonstrated to activate BDNF promoter IV in primary cortical neurons ([@CIT0049]) and upregulate BDNF expression in the rat brain ([@CIT0023]). Presumably through BDNF-TrkB receptor signaling, lithium treatment may subsequently enhance activation of its downstream effectors Akt and ERK. Moreover, Akt mediates the phosphorylation of GSK-3β while ketamine exerts its rapid antidepressant effects ([@CIT0051]). By disrupting the formation of β-arrestin 2/protein phosphatase 2A (PP2A)/Akt complex that inactivates Akt, lithium was reported to activate Akt and in turn inhibit GSK-3 ([@CIT0004]). These findings suggest a positive feedback loop and indicate that mTOR may act as a node receiving multiple upstream regulatory effects induced by lithium.

Under nutrient-deprived stress conditions, activated eEF2 kinase was found to block protein translation by phosphorylating eEF2 ([@CIT0008]). We similarly observed an increased eEF2 phosphorylation in stressed mice ([Figure 3*a*](#F3){ref-type="fig"}). Echoing this finding, other studies reported reductions in eEF2 phosphorylation in the PFC ([@CIT0009]) and hippocampus ([@CIT0003]) of rodents following ketamine administration. Moreover, ketamine-induced augmentation of BDNF synthesis was found to be eEF2 dependent ([@CIT0041]), and inhibitors of eEF2 kinase produced a fast-acting antidepressant-like effect in mice ([@CIT0003]). These results suggest that eEF2 is sensitive to stress and involved in mediating ketamine's antidepressant-like effects. In contrast to eEF2 kinase, eEF2 can be positively regulated by dephosphorylation with PP2A ([@CIT0042]). Lithium was found to upregulate PP2A activity in the rat brain ([@CIT0047]). Therefore, lithium may have multiple regulatory effects on eEF2 dephosphorylation in addition to activation of the mTOR/P70S6K signaling pathway that inhibits eEF2 kinase.

Oxidative stress plays a significant role in the pathogenesis of many neurological and psychiatric diseases such as schizophrenia and BD ([@CIT0035]). Elevated ROS production was observed from 10 minutes in mouse brains ([@CIT0014]) to 30 minutes in rat brains ([@CIT0016]) after acute injection of subanesthetic doses of ketamine. Consistently, we found that ROS production was significantly elevated 20 minutes after ketamine injection at a dose that produces antidepressant-like effects ([Figure 4](#F4){ref-type="fig"}). Many studies have shown that restraint stress increases ROS formation ([@CIT0021]). Perhaps due to the variations in severity of the restraint stress or the oxidative metabolism markers measured, we did find a trend towards increased ROS production in the brain of stressed mice, but the effect was not statistically significant.

Lithium has been reported to ameliorate ROS levels in an animal model of mania ([@CIT0022]) and suppress elevated oxidative metabolism markers, including thriobarbituric acid reactive substances and catalase in unmedicated manic patients ([@CIT0039]). The present study is the first to demonstrate that the oxidative stress induced by ketamine can be completely blocked by pretreatment with a low therapeutic dose of lithium ([Figure 4](#F4){ref-type="fig"}), underscoring lithium's neuroprotective aspects. Similar to our observations, ketamine was found to produce hyperlocomotion in rodents at doses related to its antidepressant effects ([@CIT0014]). Interestingly, antioxidant treatment inhibited ketamine-induced hyperlocomotion in mice ([@CIT0015]). In our study, treatment with a low therapeutic dose of lithium prevented ketamine-induced hyperlocomotor activity ([Figure 5*c*](#F5){ref-type="fig"}-[*d*](#F5){ref-type="fig"}). Although further experiments are needed, these data suggest that lithium's antioxidant effects may be part of its underlying mechanisms. Taken together, the antioxidant effects of lithium provide an additional benefit and justification for its adjunctive use with ketamine in the treatment of depression.

In conclusion, the present findings highlight the ability of lithium---when given in conjunction with ketamine---to augment and prolong both clinical efficacy and remission in the treatment of depression. Numerous clinical and preclinical studies have underscored ketamine's remarkable antidepressant effects. Nevertheless, given the inevitable relapse of depressive symptoms and the potential for abuse, ketamine is not a viable long-term clinical option. Thus, in providing a novel therapeutic strategy to solve this important clinical issue, our results could be of significant clinical relevance.
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